PT2751104T - Compostos e composições como inibidores de c-kit quinase - Google Patents

Compostos e composições como inibidores de c-kit quinase

Info

Publication number
PT2751104T
PT2751104T PT127568855T PT12756885T PT2751104T PT 2751104 T PT2751104 T PT 2751104T PT 127568855 T PT127568855 T PT 127568855T PT 12756885 T PT12756885 T PT 12756885T PT 2751104 T PT2751104 T PT 2751104T
Authority
PT
Portugal
Prior art keywords
compositions
compounds
kinase inhibitors
kit kinase
kit
Prior art date
Application number
PT127568855T
Other languages
English (en)
Portuguese (pt)
Inventor
Molteni Valentina
Michael James Petrassi Hank
Li Xiaolin
Liu Xiaodong
Loren Jon
Nabakka Juliet
Nguyen Bao
Yeh Vince
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2751104T publication Critical patent/PT2751104T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT127568855T 2011-09-01 2012-08-29 Compostos e composições como inibidores de c-kit quinase PT2751104T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
PT2751104T true PT2751104T (pt) 2019-12-16

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127568855T PT2751104T (pt) 2011-09-01 2012-08-29 Compostos e composições como inibidores de c-kit quinase

Country Status (30)

Country Link
US (3) US8569283B2 (enExample)
EP (1) EP2751104B1 (enExample)
JP (1) JP6134319B2 (enExample)
KR (1) KR101962495B1 (enExample)
CN (1) CN103797011B (enExample)
AP (1) AP2014007493A0 (enExample)
AR (1) AR087753A1 (enExample)
AU (1) AU2012302042B2 (enExample)
BR (1) BR112014004560A2 (enExample)
CA (1) CA2845169C (enExample)
CL (1) CL2014000492A1 (enExample)
CO (1) CO6900141A2 (enExample)
CR (1) CR20140107A (enExample)
CU (1) CU20140024A7 (enExample)
EA (1) EA026152B1 (enExample)
ES (1) ES2761332T3 (enExample)
GT (1) GT201400034A (enExample)
IL (1) IL231227A0 (enExample)
MA (1) MA35460B1 (enExample)
MX (1) MX339937B (enExample)
PE (1) PE20140909A1 (enExample)
PH (1) PH12014500372A1 (enExample)
PL (1) PL2751104T3 (enExample)
PT (1) PT2751104T (enExample)
SG (1) SG2014014369A (enExample)
TN (1) TN2014000068A1 (enExample)
TW (1) TW201313717A (enExample)
UY (1) UY34301A (enExample)
WO (1) WO2013033167A1 (enExample)
ZA (1) ZA201401175B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
JP6387488B2 (ja) 2013-01-10 2018-09-12 プルモキネ、インコーポレイテッド 非選択的キナーゼ阻害剤
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
AU2014331796B2 (en) 2013-10-11 2020-05-07 Gilead Sciences, Inc. Spray dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
MX386598B (es) 2015-07-02 2025-03-19 Janssen Sciences Ireland Uc Compuestos antibacterianos.
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
US20190256509A1 (en) * 2016-06-08 2019-08-22 Chrysalis, Inc. Histone demethylase inhibitors
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
US20200308169A1 (en) 2016-06-16 2020-10-01 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN110087653A (zh) 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
EP4272740A1 (en) 2017-05-02 2023-11-08 Novartis AG Combination therapy comprising a raf inhibitor and trametinib
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
JP2022531969A (ja) 2019-05-13 2022-07-12 ノバルティス アーゲー 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態
EP3969453A4 (en) * 2019-05-13 2023-01-18 Novartis AG CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENYL)IMIDAZO[1,2-A]PYRIDINE- 3-CARBOXAMIDE
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
MX2022003037A (es) 2019-09-13 2022-04-07 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
JP2023551434A (ja) 2020-11-19 2023-12-08 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法
CA3211532A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3212074A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AU2022240967A1 (en) 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AU2022377203A1 (en) 2021-10-28 2024-06-13 Janssen Sciences Ireland Unlimited Company Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4626884A1 (en) * 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
CN120677155A (zh) * 2022-12-07 2025-09-19 第三谐波生物股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
WO2024124002A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
BR112014003963A2 (pt) 2011-09-01 2017-03-21 Irm Llc compostos e composições como inibidores de quinase c-kit
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
KR20140105433A (ko) 2011-09-01 2014-09-01 아이알엠 엘엘씨 Pdgfr 키나제 억제제로서의 화합물 및 조성물

Also Published As

Publication number Publication date
CN103797011A (zh) 2014-05-14
US20140031333A1 (en) 2014-01-30
BR112014004560A2 (pt) 2017-04-04
TW201313717A (zh) 2013-04-01
AU2012302042A1 (en) 2014-04-17
CN103797011B (zh) 2016-03-30
CA2845169A1 (en) 2013-03-07
CA2845169C (en) 2022-04-19
PH12014500372A1 (en) 2014-04-07
US8569283B2 (en) 2013-10-29
TN2014000068A1 (en) 2015-07-01
JP2014525448A (ja) 2014-09-29
EA026152B1 (ru) 2017-03-31
JP6134319B2 (ja) 2017-05-24
WO2013033167A1 (en) 2013-03-07
KR20140075692A (ko) 2014-06-19
GT201400034A (es) 2015-02-19
US20130059832A1 (en) 2013-03-07
ES2761332T3 (es) 2020-05-19
KR101962495B1 (ko) 2019-03-26
AP2014007493A0 (en) 2014-03-31
ZA201401175B (en) 2015-01-28
US9023839B2 (en) 2015-05-05
CR20140107A (es) 2014-05-02
MA35460B1 (fr) 2014-09-01
EP2751104A1 (en) 2014-07-09
AU2012302042B2 (en) 2016-03-31
UY34301A (es) 2013-04-05
MX2014002484A (es) 2014-11-25
US8754071B2 (en) 2014-06-17
CU20140024A7 (es) 2014-04-24
IL231227A0 (en) 2014-04-30
CO6900141A2 (es) 2014-03-20
EA201490545A1 (ru) 2014-07-30
SG2014014369A (en) 2014-09-26
CL2014000492A1 (es) 2014-10-03
MX339937B (es) 2016-06-17
US20140228347A1 (en) 2014-08-14
EP2751104B1 (en) 2019-09-25
PE20140909A1 (es) 2014-07-20
PL2751104T3 (pl) 2020-04-30
AR087753A1 (es) 2014-04-16

Similar Documents

Publication Publication Date Title
ZA201401175B (en) Compounds and compositions as c-kit kinase inhibitors
AP2014007494A0 (en) Compounds and compositions as C-KIT kinase inhibitors
ZA201306221B (en) Compounds and compositions as trk inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
AP2013007252A0 (en) Heterocyclic compounds as kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201400374B (en) 4-piperidinyl compounds for use as tankyrase inhibitors
AP3597A (en) Imidazopyridazines as akt kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
ZA201404134B (en) Compositions containing kinase inhibitors
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors